Lethality

World Directed Energy Weapons Market Research Report 2023: Market to Reach $22.1 Billion by 2032 - DE Weapons are Predicted to be at the Forefront of Next Generation Weapons

Retrieved on: 
金曜日, 7月 7, 2023
Weapon, UAS, Military, THOR, Unmanned aerial vehicle, United States Department of the Army, Lethality, DE, Anti-tank guided missile, United States Army, Acquisition, Investment, Application, Tactic, Air force, United States Department of the Air Force, Arms industry

The military is investing in the integration of cutting-edge weapon systems like directed energy weapons into vehicles, which is propelling the market's expansion.

Key Points: 
  • The military is investing in the integration of cutting-edge weapon systems like directed energy weapons into vehicles, which is propelling the market's expansion.
  • Conventional blast and fragmentation weapons cannot achieve a technical breakthrough for upcoming warfare scenarios, claim military strategists and defense specialists.
  • DE weapons are predicted to meet conventional and current kinetic energy weapons' performance criteria by the middle of the 2030s.
  • The defense industry anticipated the greatest market share for directed energy weapons and is expected to grow rapidly throughout the forecast period.

The Heat Is On: How to protect your home and family from a lethally hot future

Retrieved on: 
火曜日, 5月 23, 2023
Climate, Intact Centre, Heat, University, Education, Rocky Mountains, Atmosphere, Face, City, Anxiety, Garden, Tree, Electricity, Thought, Intact, Death, Climate change, St. Lawrence River, Knowledge, Weather, University of Waterloo, News, Lethality, Seal, Medical device

The guidance spells out what residents can do to keep themselves and their loved ones safe, with actions identified for both houses and apartments/condos .

Key Points: 
  • The guidance spells out what residents can do to keep themselves and their loved ones safe, with actions identified for both houses and apartments/condos .
  • The guidelines build on the Intact Centre’s report “Irreversible Extreme Heat: Protecting Canadians and Communities from a Lethal Future”, developed with over 60 national experts.
  • “Although flooding and wildfire are the most financially costly perils affecting Canadians, extreme heat is the deadliest, by far.
  • With extreme heat already hitting the headlines this year, Canadians have no time to spare in preparing themselves for the heat events to come.

Directed Energy Weapons Market Report identifies BAE Systems Plc, Elbit Systems Ltd., and L3Harris Technologies Inc. as the Dominant Players | Technavio

Retrieved on: 
水曜日, 8月 18, 2021
EMEA, AGC Aerospace & Defense, CAGR, APAC, Defense, Non-lethal weapon, Overalls, Lethality, Growth, USD, ISR, Weapon

The directed energy weapons market is poised to grow by USD 2.91 billionduring 2021-2025, progressing at a CAGR of20.64% during the forecast period.

Key Points: 
  • The directed energy weapons market is poised to grow by USD 2.91 billionduring 2021-2025, progressing at a CAGR of20.64% during the forecast period.
  • The directed energy weapons market report covers insights on major trends, key growth drivers, and challenges impacting the overall growth of the market.
  • The report identifies the development and procurement of advanced technologies as one of the major factors driving the growth of the market.
  • The Directed Energy Weapons Market is segmented by Application (Defense and Homeland security), Geography (EMEA, Americas, and APAC), and Weapon type (Lethal and Non-lethal).

IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

Retrieved on: 
月曜日, 4月 19, 2021
Articles, Communication, Forward-looking statement, Genetics, Synthetic lethality, SEC filings, United States corporate law, Form 10-K, Financial risk, Lethality

IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.\nThis press release contains forward-looking statements, including, but not limited to, statements related to the timing, content and participants of the Synthetic Lethality Investor Day.

Key Points: 
  • IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.\nThis press release contains forward-looking statements, including, but not limited to, statements related to the timing, content and participants of the Synthetic Lethality Investor Day.
  • Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.
  • IDEAYA undertakes no obligation to update or revise any forward-looking statements.
  • For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see the IDEAYA Annual Report for the year ended December 31, 2020 on Form 10-K filed on March 23, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/ideaya-biosciences-announces-age...\n"

IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

Retrieved on: 
水曜日, 1月 15, 2020
Genetics, Synthetic lethality, Lethality

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced key research highlights from its synthetic lethality pipeline.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced key research highlights from its synthetic lethality pipeline.
  • MAT2A and Werner Helicase represent two of the most exciting synthetic lethality targets to emerge since PARP inhibitors."
  • "We are excited about the progress across our synthetic lethality pipeline targeting patient populations such as MTAP-deletion, HRD, and MSI-High.
  • We look forward to advancing our first synthetic lethality program to IND and extending our leadership in the field."